My Cholesterol Is Fine. Why Does My Cardiologist Keep Mentioning Lp(a)?
The 2022 European Atherosclerosis Society consensus and the 2026 ACC/AHA dyslipidemia guideline (in the ACC's summary) both say measure Lp(a) at least once in adulthood, and the EAS rules risk in above 50 mg/dL or 125 nmol/L. Our $30 Lp(a) test is an add-on to the Advanced package.
A standard lipid panel cannot tell you your lipoprotein(a). The 2022 European Atherosclerosis Society consensus statement recommends measuring it at least once in adults, and the 2026 ACC/AHA dyslipidemia guideline now says the same for US practice, because more than 90% of a person's Lp(a) concentration is set by genetic variation at the LPA locus and it does not move with the things that move LDL cholesterol. Your cardiologist keeps mentioning it because a normal cholesterol panel is silent about it.
This article covers what the guideline bodies say about Lp(a), what the thresholds are in the units they publish them in, why those units are a trap, and what can honestly be done about a high result today.
Why is Lp(a) not already on a standard lipid panel?
Because the cholesterol it carries is collectively reported as LDL-C.
Lp(a) is a low-density lipoprotein-like particle. The EAS statement explains the reporting problem plainly. Cholesterol contained in Lp(a) particles cannot be separated from the cholesterol in LDL particles. Your Lp(a) is quietly folded into a number that does not identify it.
The consequence is that a person can have a textbook LDL-C and a substantially elevated cardiovascular risk that the panel never showed. The EAS panel writes that elevated Lp(a) is a risk factor "even at very low levels of low-density lipoprotein cholesterol."
What does the European Atherosclerosis Society actually recommend?
Test Lp(a) at least once in adults, and read the result against the patient's absolute global cardiovascular risk.
The 2022 consensus statement, published in the European Heart Journal, makes four positions clear.
- Test Lp(a) concentration at least once in adults, and interpret the result in the context of the patient's absolute global cardiovascular risk.
- Cascade testing has potential value in familial hypercholesterolemia, or where there is a family or personal history of very high Lp(a) or premature atherosclerotic cardiovascular disease.
- Epidemiologic and genetic studies involving hundreds of thousands of people support a causal and continuous association between Lp(a) concentration and cardiovascular outcomes across different ethnicities. High Lp(a) is also associated with calcification of the aortic valve.
- Current findings do not support Lp(a) as a risk factor for venous thrombotic events or impaired fibrinolysis.
The "at least once" position follows from the biology. The LPA gene is fully expressed by age 2, and adult Lp(a) levels are usually reached by about age 5. There is little reason to repeat a measurement that does not change.
US bodies have since reached the same conclusion. The National Lipid Association's 2024 focused update states: "We now have sufficient evidence to support the recommendation to measure Lp(a) levels at least once in every adult for risk stratification." It adds that cascade screening of first-degree relatives of patients with elevated Lp(a) can identify additional individuals at risk.
What counts as a high Lp(a)?
Above 50 mg/dL, or above 125 nmol/L, is where the EAS panel rules Lp(a)-attributable risk in.
The panel is explicit that the association between Lp(a) and cardiovascular outcomes is linear, so any threshold is a pragmatic device rather than a biological cliff. With that caveat, it suggests the following cut-offs.
| Band | Mass units | Molar units | How the panel frames it |
|---|---|---|---|
| Rule out | Under 30 mg/dL | Under 75 nmol/L | Lp(a)-attributable risk can be ruled out |
| Grey zone | 30 to 50 mg/dL | 75 to 125 nmol/L | Relevant alongside other risk factors, and in risk stratification |
| Rule in | Over 50 mg/dL | Over 125 nmol/L | Lp(a)-attributable risk is ruled in |
The National Lipid Association draws its bands in the same places. Under 75 nmol/L, or 30 mg/dL, is low risk. Between 75 and 125 nmol/L, or 30 to 50 mg/dL, is intermediate risk. At or above 125 nmol/L, or 50 mg/dL, is high risk.
For scale, the EAS statement records that Lp(a) concentration in the population ranges from under 0.1 mg/dL to over 300 mg/dL, or under 0.2 to 750 nmol/L. This is a very wide distribution, and where you sit in it was largely decided before you started school.
Why are the units a genuine trap?
Because mg/dL and nmol/L are not interchangeable by a fixed number, and the EAS panel says so in as many words.
"This panel does not recommend using a standard factor to convert between mg/dL and nmol/L, as assays vary extensively." Where both units are in use, the statement describes 2 to 2.5 as "only a 'best guess'" for converting mg/dL to nmol/L, and it adopts 2.5 as an interim working factor for its own general statements.
There is a deeper reason. Lp(a) particles vary in size because of a repeat polymorphism in the apolipoprotein(a) gene. Assays built on polyclonal antibodies can under- or over-estimate concentration depending on whether a person carries small or large isoforms.
The panel notes that, strictly speaking, assays based on polyclonal antibodies cannot report in molar units at all. It recommends that laboratories include the assay name in the report so that discrepant results can be tracked across follow-up.
The practical upshot is that a number from one laboratory and a number from another are not automatically comparable, and neither is a conversion you perform yourself. What a specific result means for you is a question for the physician holding the report.
Where does the ACC/AHA guideline put Lp(a)?
Since March 2026, at least once in every adult. The 2026 ACC/AHA multisociety guideline on the management of dyslipidemia retires and replaces the 2018 cholesterol guideline.
The American College of Cardiology's summary of the new guideline says that "Lp(a) should be measured at least once in adulthood." It adds that lifestyle changes minimally affect Lp(a) levels, so repeat testing is generally not needed.
The retired 2018 guideline was narrower. It named a family history of premature atherosclerotic cardiovascular disease as a relative indication for measurement. It treated an Lp(a) of 50 mg/dL or more, or 125 nmol/L or more, as a risk-enhancing factor in a statin decision that was already close.
| Body | Who should be measured | Level it calls high |
|---|---|---|
| European Atherosclerosis Society, 2022 | At least once in adults | Over 50 mg/dL, over 125 nmol/L |
| National Lipid Association, 2024 | At least once in every adult, for risk stratification | At or above 125 nmol/L, or 50 mg/dL |
| ACC/AHA multisociety, 2026 | At least once in adulthood | Not stated in the ACC summary we could read |
| AHA/ACC multisociety, 2018, now retired | Relative indication: family history of premature ASCVD | At or above 50 mg/dL or 125 nmol/L |
On who should be tested, the three current documents now agree: once, in adulthood. What a given result means for treatment is still a question for the physician holding the report.
Why do diet and exercise not move it?
Because Lp(a) is not that kind of number.
The EAS statement attributes more than 90% of the variability in Lp(a) concentration to genetic variation at the LPA locus, with the Kringle-IV repeat polymorphism alone explaining roughly 30% to 70% of it.
The statement tabulates the non-genetic influences that have been measured.
| Influence | Effect on Lp(a) as tabulated by the EAS |
|---|---|
| Physical activity | None or minimal |
| Fasting | None |
| Replacing dietary saturated fat with carbohydrate or unsaturated fat | About a 10% to 15% increase |
| Low carbohydrate diet high in saturated fat | About a 15% decrease |
| Pregnancy | Roughly a twofold increase |
| Nephrotic syndrome | Three to fivefold increase versus control |
| Postmenopausal hormone replacement therapy | About a 25% decrease |
None of that is a treatment plan. It is a description of how immovable the number is, and it explains why the EAS recommends managing everything around Lp(a) instead.
How many people carry an elevated level?
The National Lipid Association puts it at approximately one in five individuals.
| Source | Prevalence of elevated Lp(a) as published |
|---|---|
| EAS consensus statement, 2022 | Approximately 1.4 billion people affected worldwide |
| American Journal of Cardiovascular Drugs review, 2026 | Roughly 20% of the general population above about 125 nmol/L, or 50 mg/dL or more |
| National Lipid Association, 2024 | Approximately one in five individuals |
The National Lipid Association notes that despite this prevalence, measurement rates are low.
What can be done about a high result today?
Manage the risk factors that do move, because no therapy has yet been shown to cut cardiovascular events by lowering Lp(a). The first large outcomes trial to report, in September 2026, did not show it.
Two things follow from that, and it is important to be exact about which is which.
The first is what is available now. Without specific Lp(a)-lowering therapies, the EAS recommends early intensive management of the risk factors that do move: LDL-C, blood pressure, glucose and lifestyle factors, targeted according to global cardiovascular risk and the untreated Lp(a) level.
It notes that statins may slightly increase Lp(a) but should not be discontinued, because their cardiovascular benefit far outweighs that effect. PCSK9 inhibitors produce modest Lp(a) reductions but are not registered for that purpose.
Lipoprotein apheresis sits at the far end of that list. The National Lipid Association records that the US Food and Drug Administration approved an indication for lipoprotein apheresis in high-risk patients with familial hypercholesterolemia and documented coronary or peripheral artery disease whose Lp(a) remains at or above 60 mg/dL, roughly 150 nmol/L, and whose LDL-C remains at or above 100 mg/dL on maximally tolerated lipid-lowering therapy.
The second is what is still being tested. Several drugs lower Lp(a) dramatically, and every published trial so far has measured the laboratory number rather than the clinical event.
| Trial | Drug and population | Primary endpoint as published |
|---|---|---|
| OCEAN(a)-DOSE, NEJM 2022, 281 patients | Olpasiran, established atherosclerotic cardiovascular disease with Lp(a) above 150 nmol/L | Percent change in Lp(a) from baseline to week 36 |
| ALPACA, NEJM 2025, 320 participants | Lepodisiran, median baseline Lp(a) 253.9 nmol/L | Time-averaged percent change in serum Lp(a) from day 60 to day 180 |
| Kylo-11 phase 1, The Lancet 2026, 70 dosed participants | Kylo-11, otherwise healthy adults with elevated Lp(a) | Incidence of investigator-assessed adverse events within 24 weeks |
Every one of those endpoints is a laboratory or safety measure. None of those trials was designed to show, or did show, a reduction in heart attacks or deaths.
Outcome trials are the test that matters, and the first one has now reported. On 4 September 2026 Novartis announced topline results from Lp(a)HORIZON, which gave pelacarsen or placebo to 8,323 patients with elevated Lp(a) and established cardiovascular disease.
| Outcome trial | Drug | Status as of October 2026 |
|---|---|---|
| Lp(a)HORIZON | Pelacarsen | Did not meet its primary endpoint of reducing cardiovascular events; full data to be presented at a medical congress |
| OCEAN(a)-Outcomes | Olpasiran | Still running, per its trial registry record |
| ACCLAIM-Lp(a) | Lepodisiran | Ongoing, as listed in an August 2026 review |
Novartis said the trial "did not meet its primary endpoint of reducing the risk of cardiovascular events." Pelacarsen lowered Lp(a), but the company said this did not translate into reduced cardiovascular risk in the overall study population.
One negative trial of one drug does not settle the question for the others, which work differently and lower Lp(a) further. It does mean that lowering Lp(a) is still a hypothesis with good biological support, not a demonstrated outcome benefit.
What does an Lp(a) test cost in Taipei?
We sell two ways to measure it, at two different providers, and neither is sold on its own.
| Test | Price | Where it can be added |
|---|---|---|
| Lp (a) cholesterol genetic blood test | $30 | Only to the Advanced package ($3,499) at Beitou Health Management Hospital |
| Advanced Cardiovascular Lipids Blood Panel, which includes Lp(a) | $260 | To the Convenient package ($299) or another iHope Clinic booking |
Both packages are listed on the health screening page. Our digital report is delivered 2 to 3 weeks after screening.
Our catalog does not say which assay either laboratory uses, so this article does not describe one. What the guidelines describe is a measurement of a lipoprotein concentration in blood, reported in mg/dL or nmol/L. Despite the catalog name, measuring an inherited lipoprotein concentration is not DNA sequencing, and the units caveat above applies to any such result.
If you are planning appointments around a trip, confirm the slot before you book the flight. Most screenings need a few weeks of notice, some need longer, and some can be arranged quickly. If your dates are tight it is worth asking, because arrangements are made case by case. The live booking calendar always shows the true earliest date.
Two related pieces on this site: our explainer on the coronary calcium score, and our overview of heart and lung screening in Taiwan.
The bottom line
Lp(a) is inherited, largely fixed by early childhood, invisible on a standard lipid panel, and causally associated with cardiovascular disease according to a large body of genetic and epidemiologic evidence. The European, the National Lipid Association and, since 2026, the ACC/AHA guidance all say measure it once in adulthood.
No therapy has yet been shown to reduce cardiovascular events by lowering it. The first outcome trial to report, Lp(a)HORIZON, missed its primary endpoint, and two more are running. If the number comes back high, the honest response today is to manage everything else harder, with a physician who has the report in front of them.
Sources
- European Heart Journal, Kronenberg F et al. 2022 — Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement (accessed 2026-09-09)
- PubMed Central — Full text of the 2022 EAS lipoprotein(a) consensus statement (accessed 2026-09-09)
- Circulation, 2026 — 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia (accessed 2026-10-14)
- American College of Cardiology — ACC, AHA Release New Clinical Guideline for Managing Dyslipidemia, 13 March 2026 (accessed 2026-10-14)
- Novartis — Lp(a)HORIZON Phase III topline results for pelacarsen, 4 September 2026 (accessed 2026-10-14)
- ClinicalTrials.gov — OCEAN(a)-Outcomes Trial, NCT05581303 (accessed 2026-10-14)
- Circulation, Grundy SM et al. — 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol, full text (accessed 2026-09-09)
- New England Journal of Medicine, O'Donoghue ML et al. 2022 — Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease, the OCEAN(a)-DOSE trial (accessed 2026-09-09)
- American Journal of Cardiovascular Drugs, Miramontes Gonzalez JP 2026 — Lipoprotein(a): Cardiovascular Risk and Emerging Targeted Therapies (accessed 2026-09-09)
- Journal of Clinical Lipidology, Koschinsky ML et al. 2024 — A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice (accessed 2026-09-09)
- New England Journal of Medicine, Nissen SE et al. 2025 — Lepodisiran, A Long-Duration Small Interfering RNA Targeting Lipoprotein(a), the ALPACA trial (accessed 2026-09-09)
- The Lancet, Sarraju A et al. 2026 — Safety and lipoprotein(a)-lowering effects of Kylo-11: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial (accessed 2026-09-09)